Yet, PI3K pathway mutations also occur in colorectal cancers and are often coincident with K-RAS mutations, suggesting that PI3K is not a common effector of K-RAS signaling in colon cancer [26]. This evidence concerns the gene KRAS and malignant colon neoplasm.